Cloud-Integrated Neural Interface for Personalized Electrical Stimulation Therapy
Legal Citation
Summary of the Inventive Concept
A next-generation electrical stimulation therapy system leveraging cloud-based artificial intelligence (AI) and wearable neural interface devices to provide personalized treatment protocols based on real-time brain activity and historical treatment outcomes.
Background and Problem Solved
The original patent disclosed an electrical stimulation modulation system that relied on local processing and limited physiological signal analysis. However, this approach has limitations in terms of adaptability, scalability, and efficacy. The new inventive concept addresses these limitations by introducing a cloud-based AI platform that integrates with wearable neural interface devices to provide personalized stimulation protocols, enabling more effective and efficient treatment outcomes.
Detailed Description of the Inventive Concept
The inventive concept comprises a wearable neural interface device that detects neural activity signals from a patient's brain and transmits them to a cloud-based AI platform. The AI platform analyzes the neural activity signals and generates personalized stimulation protocols based on real-time brain activity and historical treatment outcomes. The protocols are then transmitted back to the wearable device, which delivers electrical stimulation to the patient accordingly. This closed-loop system enables continuous optimization of treatment outcomes and improves patient care.
Novelty and Inventive Step
The new claims introduce the paradigm-shifting concept of integrating cloud-based AI with wearable neural interface devices to provide personalized electrical stimulation therapy. This approach is distinct from the original patent's local processing and limited physiological signal analysis, offering a significant improvement in treatment efficacy and adaptability.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different neural activity sensors, such as electroencephalography (EEG) or magnetoencephalography (MEG), or the integration of additional physiological signals, like heart rate or blood pressure, to further enhance the AI platform's analysis capabilities. Variations may also involve different AI algorithms or machine learning techniques to optimize treatment outcomes.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the medical device industry, particularly in the fields of neurology, psychiatry, and rehabilitation. The cloud-based AI platform and wearable neural interface devices can be marketed as a comprehensive solution for personalized electrical stimulation therapy, offering improved treatment outcomes and reduced healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering, specifically neural stimulation devices and signal processing technologies involving brain-computer interfaces and electrical stimulation therapy systems
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer with expertise in neural signal processing, electrical stimulation technologies, embedded medical device design, and advanced signal analysis techniques, holding a graduate degree with 3-5 years of specialized experience in neural interface technologies
Obviousness Rationale
A PHOSITA would recognize that extending the source patent's localized neural stimulation processing to a cloud-based AI platform represents a predictable technological progression in medical device design. The fundamental principles of neural signal analysis, stimulation parameter optimization, and personalized medical treatment are consistent between the source patent and the published technical disclosure. The cloud-based AI approach provides a natural evolutionary step in enhancing the adaptive capabilities of neural stimulation systems by leveraging broader data analysis and machine learning techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,790 |
|---|---|
| Title | Electrical stimulation modulation |
| Assignee(s) | Medtronic, Inc. |